Education
About Us
Working with TipRanks
Follow Us
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
ZVSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.11 - $3.37
Previous CloseN/A
Volume38.43K
Average Volume (3M)106.80K
Market Cap
$932.65K
Enterprise Value$3.19M
Total Cash (Recent Filing)$72.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Nov 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding8,095,921
10 Day Avg. Volume52,220
30 Day Avg. Volume106,803
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.42
Enterprise Value/Revenue122.23
Enterprise Value/Gross Profit281.93
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside16566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.11 and its highest was $3.37 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $932.65K.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 69 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.46.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Undervalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$0.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics (ZVSA) is a clinical stage specialty biopharmaceutical company focused on developing innovative therapies to address unmet needs in the areas of renal and inflammatory diseases. The company leverages its proprietary technologies to advance a portfolio of drug candidates aimed at improving patient outcomes and quality of life. ZyVersa's core product candidates include VAR 200 for kidney diseases and IC 100 for inflammatory conditions, which are in various stages of clinical development.
Technical Analysis
TNF Pharmaceuticals
―
Scinai Immunotherapeutics
―
Entero Therapeutics
―
Protagenic Therapeutics
―
PMGC Holdings
―
Ownership Overview
6.64%
Insiders
0.27% Mutual Funds
0.22% Other Institutional Investors
92.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---